Navigation Links
Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
Date:11/3/2008

Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The company expects that the first microRNA diagnostic tests applying its technology will be launched by licensed clinical laboratories in the United States in 2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease and the expected timing of submission for approval and launch of diagnostic tests using our microRNA technology constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of whic
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Rosetta Genomics to Present at Oppenheimers 19th Annual Healthcare Conference
2. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
3. Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative
4. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
5. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
6. Rosetta Genomics Reports Second Quarter 2008 Financial Results
7. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
8. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
9. Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference
10. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
11. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... SAN MARINO, Calif. , May 23, 2013 ... announces today a strategic alliance with DAK Renewable ... increase the corn oil yield. VG Energy is ... Inc. (OTC Pink: VGLS). VG Energy,s ... pathways to increase the oil yield in plants, ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... FL (PRWEB) May 23, 2013 On ... made trips to supermarkets to search for the growing ... store aisles. Results from a year long study were ... level in foods, specifically meats, over previous years. For ... how the growth of antibiotic resistant bacteria in food, ...
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... , , CHICAGO, Sept. 17 ... risk management services, insurance and ... issued the findings of its 2009 Clinical Trials Risk Map ... pharmaceutical and medical device companies conduct business ...
... STAMFORD, Conn., Sept. 17 Cowen Healthcare ... established a Strategic Advisory Board to extend the Firm,s ... The Board will be comprised of industry veterans with ... is expected to supplement Cowen Royalty,s due diligence, opportunity ...
... ... pharma, biotech, medical device, and software industries, among others , ... Boston, Massachusetts (Vocus) -- Brown Rudnick, an ... Godward Kronish LLP has joined the Firm,s Boston office. With over 35 years of ...
Cached Biology Technology:Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 2Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 3Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 4Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 5Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 2Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 3Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 4Veteran Intellectual Property Team Joins Brown Rudnick 2
(Date:5/23/2013)... with autologous cord blood. Following a cardiac arrest with ... been in a persistent vegetative state with minimal ... the cord blood containing stem cells, the symptoms improved ... speak simple sentences and to move. "Our findings, along ... doubts about the effectiveness of the new therapy", says ...
(Date:5/22/2013)... 2013 U.S. Forest Service scientists are part of ... from the TKF Foundation, will examine how collaborative planning ... recover from tragedy. , The TKF Foundation announced today ... selected for grant funding. In addition to research on ... recovery and resiliency, the 3-year, $585,000 grant will contribute ...
(Date:5/22/2013)... fatty acids in fish oil have long been thought ... American Heart Association currently recommends eating at least two ... in omega 3s. However, the mechanism behind this protective ... scientists led by Jason R. Carter of Michigan Technological ... that fish oil might specifically counteract the detrimental effects ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2Fish oil may help the heart beat mental stress 2
... if trains, planes and automobiles all were powered simply ... if their exhaust and by-products helped the environment? ... The salp, a small, barrel-shaped organism that resembles ... waters to feed and propel itself. Scientists believe ...
... , In one of the first efforts of its kind, UCLA ... further by showing not just the order in which genes fall ... The findings, published in the August issue of the journal ... work together and shed light on how they collaborate to help ...
... Molecular Biosensor and Imaging Center (MBIC) are turning ... probes called fluoromodules that are used to monitor ... latest advance enhances their fluormodule technology by causing ... than typical fluorescent proteins. The new fluoromodules are ...
Cached Biology News:The jellyfish-like salp: Most efficient filter-feeder in the deep, scientists discover 2The jellyfish-like salp: Most efficient filter-feeder in the deep, scientists discover 3UCLA scientists map all mammalian gene interactions 2UCLA scientists map all mammalian gene interactions 3Carnegie Mellon researchers turn up brightness on fluorescent probes 2
UCP1/2/3 (FL-307)...
... Proliferation Kit, For 100 slides. Immunocytochemistry.Sample ... in vitro tissue labeling.Recommended cell number: ... (labeling 1-2 hours).Store at 2-8 C ... Category: Drug Screening & Cellular Assays, ...
... isolation and affinity purification of small ... Hydrophobic, monodisperse magnetic particles (2.8 m ... further surface activation is not required. ... optimal orientation for affinity purification of ...
... Anti-phospho-Ser/Thr-Pro, MPM-2, agarose conjugate ... sodium azide Quality ... immunoprecipitating mitotic MPM2 antigens ... HeLa cells as shown ...
Biology Products: